231 related articles for article (PubMed ID: 21622723)
21. Molecular Pathways: Targeting Cancer Stem Cells Awakened by Chemotherapy to Abrogate Tumor Repopulation.
Chan KS
Clin Cancer Res; 2016 Feb; 22(4):802-6. PubMed ID: 26671994
[TBL] [Abstract][Full Text] [Related]
22. Cancer stem cells: the development of new cancer therapeutics.
Scatena R; Bottoni P; Pontoglio A; Giardina B
Expert Opin Biol Ther; 2011 Jul; 11(7):875-92. PubMed ID: 21463158
[TBL] [Abstract][Full Text] [Related]
23. Acquisition of epithelial-mesenchymal transition phenotype and cancer stem cell-like properties in cisplatin-resistant lung cancer cells through AKT/β-catenin/Snail signaling pathway.
Wang H; Zhang G; Zhang H; Zhang F; Zhou B; Ning F; Wang HS; Cai SH; Du J
Eur J Pharmacol; 2014 Jan; 723():156-66. PubMed ID: 24333218
[TBL] [Abstract][Full Text] [Related]
24. Medulloblastoma cancer stem cells: molecular signatures and therapeutic targets.
Bahmad HF; Poppiti RJ
J Clin Pathol; 2020 May; 73(5):243-249. PubMed ID: 32034059
[TBL] [Abstract][Full Text] [Related]
25. Therapeutic considerations of PARP in stem cell biology: Relevance in cancer and beyond.
Zeniou M; Nguekeu-Zebaze L; Dantzer F
Biochem Pharmacol; 2019 Sep; 167():107-115. PubMed ID: 31202733
[TBL] [Abstract][Full Text] [Related]
26. Targeting cancer stem cells to suppress acquired chemotherapy resistance.
Vidal SJ; Rodriguez-Bravo V; Galsky M; Cordon-Cardo C; Domingo-Domenech J
Oncogene; 2014 Sep; 33(36):4451-63. PubMed ID: 24096485
[TBL] [Abstract][Full Text] [Related]
27. Translational potential of cancer stem cells: A review of the detection of cancer stem cells and their roles in cancer recurrence and cancer treatment.
Islam F; Gopalan V; Smith RA; Lam AK
Exp Cell Res; 2015 Jul; 335(1):135-47. PubMed ID: 25967525
[TBL] [Abstract][Full Text] [Related]
28. Combination therapy with epigenetic-targeted and chemotherapeutic drugs delivered by nanoparticles to enhance the chemotherapy response and overcome resistance by breast cancer stem cells.
Li SY; Sun R; Wang HX; Shen S; Liu Y; Du XJ; Zhu YH; Jun W
J Control Release; 2015 May; 205():7-14. PubMed ID: 25445694
[TBL] [Abstract][Full Text] [Related]
29. Multiple end-point analysis reveals cisplatin damage tolerance to be a chemoresistance mechanism in a NSCLC model: implications for predictive testing.
Almeida GM; Duarte TL; Farmer PB; Steward WP; Jones GD
Int J Cancer; 2008 Apr; 122(8):1810-9. PubMed ID: 18074354
[TBL] [Abstract][Full Text] [Related]
30. Cancer drug resistance: an evolving paradigm.
Holohan C; Van Schaeybroeck S; Longley DB; Johnston PG
Nat Rev Cancer; 2013 Oct; 13(10):714-26. PubMed ID: 24060863
[TBL] [Abstract][Full Text] [Related]
31. Hypoxia-mediated cancer stem cell resistance and targeted therapy.
Sun X; Lv X; Yan Y; Zhao Y; Ma R; He M; Wei M
Biomed Pharmacother; 2020 Oct; 130():110623. PubMed ID: 32791395
[TBL] [Abstract][Full Text] [Related]
32. The effectiveness of an anti-human IL-6 receptor monoclonal antibody combined with chemotherapy to target colon cancer stem-like cells.
Ying J; Tsujii M; Kondo J; Hayashi Y; Kato M; Akasaka T; Inoue T; Shiraishi E; Inoue T; Hiyama S; Tsujii Y; Maekawa A; Kawai S; Fujinaga T; Araki M; Shinzaki S; Watabe K; Nishida T; Iijima H; Takehara T
Int J Oncol; 2015 Apr; 46(4):1551-9. PubMed ID: 25625841
[TBL] [Abstract][Full Text] [Related]
33. Potential molecular, cellular and microenvironmental mechanism of sorafenib resistance in hepatocellular carcinoma.
Chen J; Jin R; Zhao J; Liu J; Ying H; Yan H; Zhou S; Liang Y; Huang D; Liang X; Yu H; Lin H; Cai X
Cancer Lett; 2015 Oct; 367(1):1-11. PubMed ID: 26170167
[TBL] [Abstract][Full Text] [Related]
34. Mechanisms of Disease: cancer stem cells--targeting the evil twin.
Trumpp A; Wiestler OD
Nat Clin Pract Oncol; 2008 Jun; 5(6):337-47. PubMed ID: 18431377
[TBL] [Abstract][Full Text] [Related]
35. Let-7d miRNA Shows Both Antioncogenic and Oncogenic Functions in Osteosarcoma-Derived 3AB-OS Cancer Stem Cells.
Di Fiore R; Drago-Ferrante R; Pentimalli F; Di Marzo D; Forte IM; Carlisi D; De Blasio A; Tesoriere G; Giordano A; Vento R
J Cell Physiol; 2016 Aug; 231(8):1832-41. PubMed ID: 26679758
[TBL] [Abstract][Full Text] [Related]
36. Targeting cancer stem cells for more effective therapies: Taking out cancer's locomotive engine.
Winquist RJ; Boucher DM; Wood M; Furey BF
Biochem Pharmacol; 2009 Aug; 78(4):326-34. PubMed ID: 19539800
[TBL] [Abstract][Full Text] [Related]
37. Existing drugs and their application in drug discovery targeting cancer stem cells.
Lv J; Shim JS
Arch Pharm Res; 2015 Sep; 38(9):1617-26. PubMed ID: 26152874
[TBL] [Abstract][Full Text] [Related]
38. CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway.
Ma S; Lee TK; Zheng BJ; Chan KW; Guan XY
Oncogene; 2008 Mar; 27(12):1749-58. PubMed ID: 17891174
[TBL] [Abstract][Full Text] [Related]
39. Dopamine enhances the response of sunitinib in the treatment of drug-resistant breast cancer: Involvement of eradicating cancer stem-like cells.
Wang S; Mou Z; Ma Y; Li J; Li J; Ji X; Wu K; Li L; Lu W; Zhou T
Biochem Pharmacol; 2015 May; 95(2):98-109. PubMed ID: 25824241
[TBL] [Abstract][Full Text] [Related]
40. Cytoplasmic levels of cFLIP determine a broad susceptibility of breast cancer stem/progenitor-like cells to TRAIL.
French R; Hayward O; Jones S; Yang W; Clarkson R
Mol Cancer; 2015 Dec; 14():209. PubMed ID: 26667821
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
